Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 12/20 | 0.54 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26078856 | 0.81 | CYP19A1 (0.36) | GAAMAPK1HTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL18181914 | 0.80 | GAA (0.64) | GAAMAPK1HTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL22571079 | 0.77 | GAA (0.64) | GAAMAPK1HTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL22571078 | 0.77 | GAA (0.64) | GAAMAPK1HTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL20215073 | 0.76 | CYP19A1 (0.46) | GAAMAPK1HTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL25599627 | 0.75 | MT-CO2 (0.38) | GAAMAPK1HTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL12301782 | 0.74 | CYP19A1 (0.33) | — | |
| SCHEMBL12330963 | 0.73 | CYP19A1 (0.49) | GAASMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL12394202 | 0.72 | HTT (0.40) | MAPK1HTTSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL24235519 | 0.72 | CYP19A1 (0.31) | SMN1; SMN2ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200071735-A1 | Compounds for Increasing Lipid Synthesis and Storage | WASE, NISHIKANT | 2020-03-05 | — | — | US | disclosed |
| US-10351883-B2 | Compounds for increasing lipid synthesis and storage | NUTECH VENTURES (US) | 2019-07-16 | — | — | US | disclosed |
| US-20160312253-A1 | Compounds for Increasing Lipid Synthesis and Storage | INVITROGEN CORPORATION | 2016-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160312253-A1 | Compounds for Increasing Lipid Synthesis and Storage | FASN, LIPC, SREBF2 | GAA 364/4885MAPK1 3804/4885HTT 3738/4885 |
| US-10351883-B2 | Compounds for increasing lipid synthesis and storage | FASN, LIPC, SREBF2 | GAA 364/4885MAPK1 3804/4885HTT 3738/4885 |
| US-20200071735-A1 | Compounds for Increasing Lipid Synthesis and Storage | FASN, LIPC, SREBF2 | GAA 364/4885MAPK1 3804/4885HTT 3738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.